Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2026 08:00 ET | Source: Pheast Therapeutics

Pheast Therapeutics Advances PHST001, an IgG4 Anti-CD24 Monoclonal Antibody, into Phase 1b Combination Cohorts

First patient dosed in Phase 1b portion of ongoing Phase 1 study evaluating PHST001 in combination with chemotherapy Company to present three abstracts at AACR 2026, including preliminary clinical...